ANNUAL REPORT “With $100 Million

FROM IDEA

2016 IMPACT ANNUAL REPORT “With $100 million

invested in over 500 Dear Friends,

In 2016, we reached a remarkable milestone—$100 million invested in drugs to Dr. Paul Newhouse | Clinical Phase 1 of the best ideas for prevent and treat Alzheimer’s disease. Dr. Newhouse and his colleague Dr. Rook are testing VU0467319, a drug that targets synapses and Alzheimer’s, our strategy When we founded the Alzheimer’s Drug Discovery Foundation in 1998, there PAGE 7 may prevent loss of cognitive function. is having an impact.” LETTER weren’t many drugs being developed for this disease. We set out to change that. Our strategy was to identify promising ideas to prevent and treat Alzheimer’s, FROM OUR and then support the pioneering researchers who could pursue them. From the beginning, we offered funding globally to researchers working in academia and the FOUNDERS biotechnology industry, because we never wanted to say no to a potential cure. Today, with $100 million invested in over 500 of the best ideas for Alzheimer’s, our strategy is having an impact. There are more treatments in clinical trials—the final Dr. Scott Turner | Clinical Phase 2 stages of a drug’s development—than ever before. The ADDF has supported over Dr. Turner’s trial is using the cancer drug nilotinib, 20% of them, which is more than any other charity. which has shown promise for treating Alzheimer’s PAGE 8 and many other neurodegenerative diseases. The generosity of our fellow Board members and all of the ADDF’s donors ensures that the best ideas to treat Alzheimer’s will make it into the hands of patients.

Together we will conquer Alzheimer’s disease.

With our deepest thanks,

Dr. Michela Gallagher | Clinical Phase 3 Dr. Gallagher’s drug, AGB 101, targets brain hyperactivity, an innovative approach that LEONARD A. LAUDER RONALD S. LAUDER may slow or even prevent the onset of Co-Chairman and Co-Founder Co-Chairman and Co-Founder PAGE 9 Alzheimer’s disease.

1 “Our strategic investments LETTER have resulted in a diverse FROM OUR portfolio of drugs in clinical Dear Friends,

trials, which increases our This was an important year for the clinical development of In 2016, our portfolio included 20 programs in clinical EXECUTIVE Alzheimer’s treatments. There were some high-profile fail- trials. Among them is a first-in-class drug targeting a chances of success.” ures, including Eli Lilly’s aducanumab. But there were many critical pathway involved in cognition being developed DIRECTOR GENETICS & more success stories, as promising drugs kept advancing. at Vanderbilt University (featured on page 7), which just EPIGENETICS entered Phase 1 trials thanks to ADDF funding. And at APOE4 is the most signif- In 2016, the Alzheimer’s Drug Discovery Foundation Georgetown University, Dr. R. Scott Turner is already THESE TARGETS ARE ONLY A FEW OF THE icant genetic risk factor invested over $16 million to fund 46 new drug programs. recruiting patients for his Phase 2 trial of nilotinib, a drug INNOVATIVE APPROACHES WE ARE ADVANCING NEUROTRANSMITTERS for late-onset Alzheimer’s And for the first time in our history, we spent the majority originally developed for cancer that has shown great As we age, certain cognitive disease. New therapies may of that annual investment on clinical trials. promise for treating Alzheimer’s and other neurodegener- functions decline, a process known modify this risk as well as ative diseases (see page 8). as cognitive aging. Researchers alter how certain genes are The programs the ADDF supports are innovative. Most INFLAMMATION are exploring several strategies to expressed (i.e., epigenetics). pharmaceutical companies have focused exclusively It takes a lot of determination and resources to go from Chronic inflammation in the brain can improve cognitive function, such as on anti-amyloid drugs, but the ADDF chose to follow an idea to a drug that has a lasting impact on patients’ accelerate Alzheimer’s, and may be a NEUROPROTECTION enhancing neurotransmitters and another path. We know that aging is leading risk factor for lives. Thanks to the commitment of our funded scientists, trigger for the disease. Scientists are As Alzheimer’s pro- synaptic function. Alzheimer’s disease. And the drug programs we support donors, and partners, we are closer than we’ve ever been developing drugs that protect against gresses, neurons begin are based on the biology of aging, with targets including to conquering Alzheimer’s disease. damage while preserving normal to die, causing loss inflammation, neuroprotection, and epigenetics. inflammatory responses. of memory and other cognitive functions. MISFOLDED PROTEINS Our strategic investments have resulted in a diverse Neuroprotective drugs In neurodegenerative diseases, mis- portfolio of drugs in clinical trials, which increases our HOWARD FILLIT, MD seek to shield these folded proteins such as beta-amyloid, chances of success. This is important because we believe Founding Executive Director and Chief Science Officer brain cells from damage TDP-43, and tau accumulate, causing that Alzheimer’s is going to require a combination of and death. damage to brain cells. Scientists drugs to effectively treat it, like heart disease or diabetes. are pursuing several approaches to prevent or clear these toxic protein accumulations.

2 3 TAKING A You’ve made some potential drugs and now need evidence of safety and effectiveness. You have to address any Not every idea advances this far, issues with side effects or interactions but more and more of the programs DRUG FROM From there, you screen thousands or with targets other than the one you the ADDF supports are reaching the even millions of chemical compounds intended. What worked in a Petri dish clinic. Clinical trials happen in three to find a precious few that interact may not work in an animal, and if it phases, and those with good results IDEA TO with the target the way you want. doesn’t, you go back a few steps. in Phase 3 can apply for FDA approval. IMPACT Screening Preclinical Testing Clinical Trials

THE PIPELINE 1 2 3 4 5 6 Developing a drug is not easy. It takes, on average, 12 years and $2 billion to go from an idea in the head of a scientist to a pill in the hands of a patient.

Target ID & Validation Lead Discovery & Optimization IND Application In the following pages,

The process begins by identifying Now you use medicinal chemistry to If your drug appeared to work in we highlight drugs what you want the drug to do, what develop each compound into an actual preclinical tests, you can submit an in the final stages of “target” it needs to affect to slow or drug. It has to be able to cross the blood- Investigational New Drug (IND) ap- stop Alzheimer’s disease. brain barrier to reach the parts of the plication to the FDA and, if approved, development, being brain damaged in Alzheimer’s, which is finally move to human clinical trials. tested in patients who no easy feat. You keep improving the compounds until you’ve got just a few need them. drugs you can use in preclinical testing.

4 5 CLINICAL IND PHASE 1 Dr. Paul Newhouse and Dr. Jerri Rook / Vanderbilt University APPLICATION In Phase 1 clinical trials, a drug is tested in people for the first time. These early-stage trials evaluate a drug’s safety and potential side effects and try to determine the op- Dr. Leen Kawas / M3 Biotechnologies timal dose. These trials are short, involve a small number of (often healthy) people, Before researchers can begin clinical trials of a drug, they must submit an Inves- and cost an average of $4 million1 in Alzheimer’s and other neurological diseases. tigational New Drug (IND) application to the FDA and be approved. The process is designed to make sure that any treatment being tested on people is reason- In 2016, we awarded $1.27 million to Paul Newhouse, MD and Jerri Rook, PhD at ably safe. Vanderbilt University to support a Phase 1 trial of their drug, VU0467319. We began funding this program in 2011, when it was just an idea for a drug. Submitting an IND is mandatory and expensive, but very few funders are willing to support the process. At the ADDF, we understand that every step in getting a Dr. Newhouse explains: “One of the most gratifying parts of this research is making drug closer to patients is important. Last year, we awarded $1.4 million to M3 Bio- it to the clinic. After years and years of development, you finally have a drug and technologies to complete its IND application and, if approved, advance to a Phase can give it to people. The ADDF’s funding was instrumental in getting VU0467319 1a clinical trial. to this point.”

M3’s founder, Dr. Leen Kawas, remarks: “M3 has one goal in mind—get an effective VU0467319 targets synapses, the spaces where signals pass between our brain cells. Alzheimer’s drug into the hands of patients who need it. Thanks to this funding, Current drugs for Alzheimer’s disease increase levels of a transmitter that carries we are one step closer.” the signals, but these only alleviate symptoms temporarily. VU0467319 instead focuses on a synaptic receptor, called M1, which “catches” those signals. Previous Dr. Kawas has developed a small-molecule drug with the potential to restore cogni- drugs targeting M1 failed due to negative side effects. With ADDF funding, Dr. Ne- tive function in Alzheimer’s patients. The drug, NDX-1017, activates a specific type whouse and Dr. Rook tried a different approach to M1, which appears to alleviate of neurotrophic growth factor in the brain. These growth factors help neurons sur- symptoms and prevent losses in cognitive function without the side effects. vive, which could dramatically slow the progression of Alzheimer’s disease. After this trial, they will know whether their drug is safe enough to be tested in Alzheimer’s patients.

1 https://aspe.hhs.gov/report/examination-clinical-trial-costs-and-barriers-drug-development

6 7 CLINICAL PHASE 2 CLINICAL Dr. R. Scott Turner / Georgetown University Medical Center In Phase 2 trials, drugs are tested for effectiveness. If earlier trials proved that PHASE 3 the drug was safe, it can then be given to small groups of patients. In this stage, Dr. Michela Gallagher / Agenebio researchers evaluate whether the drug affects its target and if that helps slow or stop the disease. If a Phase 2 trial finds evidence that a drug is effective, it can move ahead to phase 3 clinical trials. Very few drugs have made it this far in Alzheimer’s, though the ADDF’s The cost of a Phase 2 trial can range from a few million to tens of millions of dol- investments are changing that. lars, depending on its scope and duration. These costs include manufacturing the drug and placebo, recruiting and reimbursing patient volunteers, and performing Phase 3 trials can cost hundreds of millions of dollars, involve thousands of pa- diagnostic tests, (e.g., PET scans, MRIs, blood tests), as well as covering physician, tients, and last five years or more. Because of the cost and complexity, many late- nurse, and administrative staff time, study site fees, and data collection and analysis. stage drug trials are supported by pharmaceutical companies and governments.

In 2016, we made a $2.1 million grant to R. Scott Turner, MD, PhD, of Georgetown AGB 101—a drug developed by Dr. Michela Gallagher at Agenebio that we first University Medical Center to test whether a cancer drug could be repurposed funded in 2010—is now planning Phase 3 trials. To accelerate this process, the to treat Alzheimer’s disease. Dr. Turner and his colleagues are planning a trial of ADDF has committed funding to Agenebio to formulate an extended release daily low-dose nilotinib—a drug already FDA-approved for leukemia. Earlier research pill at the effective dose found in an earlier stage trial. at Georgetown found that nilotinib triggers a process (called autophagy) that clears out toxic protein aggregates, including tau and beta-amyloid, from neu- Most Alzheimer’s drugs that have advanced to phase 3 trials in recent years have rons in the brain. By repurposing an already approved drug, the team used avail- all had the same target—beta-amyloid. And so far, all have failed. But we are opti- able safety data, including completed Phase 1 studies, to markedly accelerate the mistic. AGB 101 is targeting brain hyperactivity, an innovative approach that has drug discovery process. shown a lot of potential to slow the progression of mild cognitive impairment (MCI) to Alzheimer’s disease. There are currently no treatments approved for Dr. Turner and his colleagues are already recruiting patient volunteers in the Wash- MCI, and AGB 101 may slow this early stage enough that patients never develop ington, D.C. area. If they find evidence of effectiveness in this trial, the next step clinical Alzheimer’s. is a larger Phase 3 trial conducted at multiple research sites across the country.

8 9 Cognive BRINGING Vitality

Alzheimer’s prevention is a critical part of GREAT MINDS our mission. In 2016, we launched a new and expanded CognitiveVitality.org. The stream- BUILDING A lined, easy-to-navigate site provides credible, science-backed information on ways to improve TOGETHER brain health and prevent dementia. Each year, the Alzheimer’s Drug Discovery Foundation organizes several conferences to increase the PREVENTION CognitiveVitality.org features clear, unbiased number of researchers working on Alzheimer’s drugs and support those already in the field. ratings on food and drinks, drugs, and vitamins and supplements that may benefit the brain. The site also features a blog with in-depth articles on poten- In February, we hosted New York City Drug from biotechnology companies shared case Our final conference was also our largest. We wel- BLUEPRINT tial risks, lifestyle factors, and emerging science. Discovery: An Educational Course on studies and Voyager Therapeutics’ Steven Paul, comed researchers to Jersey City, NJ, in September Translating Research into Drugs. This one- MD delivered a powerful keynote: “Gene Therapy for our 17th International Conference on The neuroscientists behind CognitiveVitality.org day session helped to foster the city’s growing Strategies for Treating or Preventing Alzheimer’s Alzheimer’s Drug Discovery. This year’s con- constantly review new research, which they use to biotechnology sector and provided a drug Disease and Related Neurodegenerative Disorders.” ference focused on two pioneering approaches to update the site and inform our efforts to advance discovery primer to local academic scientists. treating Alzheimer’s: inflammation and neuropro- effective drugs for Alzheimer’s disease. Over the In May, we brought the Drug Discovery for tection. We also devoted a full day to sessions on next year, we plan to build on what we’ve learned A month later, we convened the 10th Drug Neurodegeneration Conference to Europe clinical trials. The ADDF is uniquely positioned to and push the field forward by funding more stud- Discovery for Neurodegeneration for the first time. This iteration, which was held in offer such an innovative program because we have ies in prevention. Conference in Miami, FL. It is designed as an Budapest, focused on drug discovery challenges supported more Alzheimer’s clinical trials than any educational course and delves into the process of unique to researchers working outside the U.S. and other nonprofit and began funding fresh approach- creating a drug. Sessions covered how to obtain featured presenters from leading European univer- es over a decade ago. An attendee noted that we funding and get started, overcome challenges sities, pharmaceutical companies, and biotechs, presented “new Alzheimer’s disease targets long in pharmacology and medical chemistry, create including AbbVie and Oryzon Genomics. before ‘big pharma’ tackles them.” clinical drug candidates, navigate the FDA, and commercialize an approved drug. Representatives

10 11 Carmela R. Abraham | Boston University School of Medicine Roberta Diaz Brinton | University of Southern California OUR Nigel Cairns | Washington University in St. Louis Mauro Costa-Mattioli | Baylor College of Medicine Alpaslan Dedeoglu | Boston University School of Medicine Pontus Forsell | AlzeCure Foundation PORTFOLIO NEUROPROTECTION Mark Gurney | Tetra Discovery Partners New & Ongoing Programs in 2016 Leen Kawas | M3 Biotechnology, Inc. Chien-liang Lin | Ohio State University John E. Lisman | Brandeis University Frank M. Longo | PharmatrophiX Hyung Jin Ahn | The Rockefeller University Peter Nelson | University of Kentucky Research Foundation Narayan Bhat | Medical University of South Carolina Christopher Norris | University of Kentucky Research Foundation Sandra Black | University of Toronto Michael Peel | Cypralis Ltd

NEURO- Allan Levey | Emory University School of Medicine Yan Jessie Zhang | The University of Texas at Austin Paul Newhouse | Vanderbilt University Medical Center Vincent Zurawski | Varinel Inc. TRANSMITTERS Lead Discovery & Lead Discovery & Target ID & Validation Screening Optimization Preclinical IND Clinical Target ID & Validation Screening Optimization Preclinical IND Clinical

*Arrow points to stage of funding in 2016; length of arrow not indicative of duration of funding.

Luca Ferraro | University of Ferrara MISFOLDED PROTEINS Giovanna Mallucci | Cambridge University INFLAMMATION Joseph Foss | NeuroTherapia, Inc. Salvatore Oddo | Banner Sun Health Research Institute Thota Ganesh | Emory University Yukari Perrella | Yuma Therapeutics Corporation Milton Greenberg | Vivreon Biosciences, LLC Brent Stockwell | Columbia University Gilles Guillemin | Macquarie University Raymond Scott Turner | Georgetown University Philip Haydon | GliaCure, Inc. Xinglong Wang | Case Western Reserve University School of Medicine Clive Holmes | University of Southampton Masashi Kitazawa | UC Irvine Alexandros Makriyannis | Northeastern University Ronald Crystal | Weill Medical College of Cornell University Paolo Pevarello | Axxam SpA Bradley Hyman | Harvard Medical School Thadd Reeder | Glialogix, Inc. Berkley Lynch | Rodin Therapeutics John Schetz | University of North Texas Health Science Center Tamara Maes | Oryzon Genomics, S.A. Paul Thompson | University of Massachusetts Pavel Petukhov | University of Illinois at Chicago Shijun Zhang | Virginia Commonwealth University Evgeny Rogaev | UM - Lowell Danna Zimmer | University of Maryland School of Medicine Xiang (Simon) Wang | Howard University College of Pharmacy GENETICS & EPIGENETICSGENETICS &

Lead Discovery & Lead Discovery & Target ID & Validation Screening Optimization Preclinical IND Clinical Target ID & Validation Screening Optimization Preclinical IND Clinical

*Arrow points to stage of funding in 2016; length of arrow not indicative of duration of funding.

14 15 Mitochondria PORTFOLIO BY Neuro- Neuro- Misfolded Genetics & Vascular Inflammation & Metabolic Other Biomarkers Prevention transmitters protection Proteins Epigenetics PERCENTAGE Function

James Bennett | Virginia Commonwealth University BIOMARKERS: These tools assess the presence and progress of disease and are critical for conducting clinical trials. Paul Edison | Imperial College London Adam Boxer | University of California, San Francisco Gerard Nuovo | Gnome Diagnostics, LLC. Gary Gibson | Winifred Masterson Burk Medical Research Institute Mari DeMarco | University of British Columbia Ashish Raj | BrainWire LLC FUNCTION Christian Holscher | Lancaster University Steven Estus | University of Kentucky Research Foundation Blaine Roberts | Howard Florey Institute & METABOLIC METABOLIC & Keith St. Lawrence | Lawson Health Research Institute

MITOCHONDRIA MITOCHONDRIA Eugenia Trushina | Mayo Clinic Rochester Els Fieremans | New York University School of Medicine Massimo Filippi | Fondazione Centro San Raffaele Charlotte Teunissen | VU University Medical Center Sam Gandy | Mount Sinai Neil Vasdev | Massachusetts General Hospital Matthew Disney | The Scripps Research Institute Lawrence Honig | Columbia University Dominic M. Walsh | Brigham & Women’s Hospital Edward Huey | Columbia University Jacob Hooker | Massachusetts General Hospital Peter Working | Alzeca Biosciences OTHER David Knopman | National Biomedical Research Ethics Council, INC Sharon Inouye | Hebrew SeniorLife Ying Wu | NorthShore University HealthSystem Research Institute Krista Lanctôt | University of Toronto Daniel Javitt | Columbia University Medical Center Richard Mohs | Global Alzheimer’s Platform Foundation Michelle Mielke | Mayo Clinic Rochester Scott Sneddon | Sharp Edge Labs, Inc Michael Weiner | UC San Francisco PREVENTION: These investments include comparative effectiveness and clinical research of prevention strategies. David Wholley | FNIH Deborah Blacker | Harvard Medical School Nathalie Pochet | Brigham & Women’s Hospital Marek Brzezinski | UC San Francisco Galit Weinstein | Boston University School of Medicine Lead Discovery & Lenore Launer | National Institute on Aging Target ID & Validation Screening Optimization Preclinical IND Clinical

*Arrow points to stage of funding in 2016; length of arrow not indicative of duration of funding.

16 17 Tenth Annual Second Annual EVENT CONNOISSEUR’S DINNER GOODES PRIZE Our annual gala on April We were proud to present 28, 2016, in New York City the 2016 Goodes Prize to HIGHLIGHTS honored Ronald S. Lauder for Daniel Martin Watterson, his leadership. The evening PhD on September 22 in New In 2016, we celebrated leaders in Alzheimer’s philanthropy and featured an exclusive art York City, for his discovery research. We thank everyone who came together and supported preview and wine pairings and development of novel Dr. Daniel Martin Watterson, Nancy Goodes, Dr. Howard Leonard A. Lauder, Ronald S. Lauder, William P. Lauder our events. presented by Sotheby’s. therapies for Alzheimer’s. Fillit, Michelle MacDonald, Melanie Caceres, David Goodes Stephen Toma, Randal Sandler

Seventh Annual FALL SYMPOSIUM & LUNCHEON Hosted by Paula Zahn, our luncheon on November 14, 2016, in New York honored philanthropist and President Eleanora Kennedy, Judy Glickman Lauder, Sheila J. Robbins, Thomas and Heidi of Advance Publications, Inc., Sharon Sager McWilliams Jo Carole Lauder, Laurie Tritsch, Ronald S. Lauder Leonard A. Lauder, Donald Newhouse Donald E. Newhouse.

Sixth Annual GREAT LADIES LUNCHEON & FASHION SHOW On April 13, 2016, we gathered in Washington, D.C. to honor Trish and George Vradenburg. Trish sadly passed away in 2017, but we remain committed to Elise and Marc Lefkowitz, Sheila C. Johnson, Martha Slagle Trish and George Vradenburg, Nancy Goodes Paula Zahn George Krupp, Leana Krupp, Liz Krupp Gregor Medinger and Gary Lauder continuing her important work.

18 19 Diana and Stephen Elkin The Mount Sinai Jan Willinger and Douglas Durst Nina B. Matis OUR SUPPORTERS FedEx Corporation Medical Center Robert Spiegel Micki and Lanny Edelsohn Bettye Musham First Manhattan Co. Melanie and Peter Munk Paula Zahn Father’s Day/Mother’s Day Pamela J. Newman First Republic Bank Neiman Marcus Group, Inc. Alison and Boniface Zaino Council, Inc. Laura and Richard Parsons We are deeply grateful to The Estée Lauder The Calvin Klein Family Georgia Melenikiotou- Sotheby’s Claire Foerster and John Paulson Aerin and Eric Zinterhofer Elizabeth W. Galvin Kathleen and Michael Pierce all those who supported our Companies Inc. Foundation Garinois and Philippe Garinois Tishman Speyer Properties, LP Daniel S. Bernstein Thomas Pheasant Salvatore Zizza Robin and David Gerson Phebe Farrow Port and work in 2016. Your generosity The David A. and Mildred H. Estate of Evelyn H. Lauder Julie and Philip Geier Staples Business Advantage Fox Family Foundation Denise Rich Carol and Henry Goldberg Thomas David Port gives us hope for a future Morse Charitable Trust Laurence C. Leeds, Jr. Kamila and Munib Islam The Starr Foundation Mary Ann Fribourg Roche $5,000–$9,999 David Goodes Principal Building Services without Alzheimer’s disease. Dennis Mullen Elise and Marc Lefkowitz Harry P. Kamen Jennifer and Mark Styslinger Barbara and Richard Furman Joanna and Daniel Rose Anonymous Marjorie and Ellery Gordon Cobey and Robert Rapaport Samuel I. Newhouse Eli Lilly and Company Howard T. Kaneff Giselle Wagner and David Geffen May and Samuel Rudin Pennie and Gary Abramson Michal Grayevsky Sharon and Daniel Roitman $500,000 and above Foundation, Inc.* Sharon and Robert Prince Amy and Mitchell Kaneff Paul Myerson Howard Gilman Foundation Family Foundation Judy Angelo Audrey and Martin Gruss Sheila J. Robbins Anonymous Phoebe and Edwin Rice Anne and J. Christopher Reyes Laura and Gary Lauder Carol and Michael Weisman Amy Gips William C. Rudin Mercedes T. Bass Judith Jackson and Rodin Therapeutics Association for Frontotemporal Lady Lynn Forester de Yosun and Olivier Reza The Ralph and Ricky Lauren Marta Gucovsky and Sharon Sager and Belk, Inc. Bruce Haims Edith and Gerald Schaeffer Degeneration* Rothschild and Sir Evelyn de Nathan E. Saint-Amand Family Foundation, Inc. $10,000–$24,999 Edward Blank J. Loring Swasey Tina and Simon Beriro The Marc Haas Foundation Finley and Patrick Shaw Judy and Leonard A. Lauder* Rothschild Pam and Allen B. Swerdlick Bonnie Englebardt Lautenberg Ronald A. Altman Ann Zimmerli-Haskel and Patricia B. Sagon Alecia and William Blake Hertog Foundation, Inc. Eileen Shields-West Jo Carole and Ronald S. Lauder* Lizabeth Furman Sandler and Ann and Andrew Tisch Beatrice Liu and Philip Lovett Jennifer and Claude Amadeo James Haskel Laura Landro and Faith Bobrow Mellody L. Hobson The Shoreland Foundation The Lauder Foundation Randal Sandler The Toma Family Susan Lloyd Aon Foundation Susan and Roger Hertog Richard Salomon Evelyn Brandt The Jaffe Family Foundation Alice Shure Susan and Thomas Lowder* Charles and Helen Schwab Wendy Wilshin and Macy’s Inc. Arcade Beauty KLD Foundation Karen and Nathan Sandler Jill and Daniel Brigati Kiera and Christopher Johnson Julie and David Silver Foundation Ronald Dickerman Nancy and Howard Marks Shelley and Robert Banks June and Louis Kay Joan and George Schiele Bobbi Brown and Katy Kamen Marilyn and James Simons $250,000–$499,000 Joan Sutton Straus The Northern Trust Company Baron Capital Foundation David H. Komansky June and Paul Schorr Steven Plofker Eleanora R. Kennedy Charitable Fund Anonymous $25,000–$49,999 Nucor Construction Corp. William K. Bowes, Jr. Foundation Liz and George Krupp Trish and Steven Shapiro Bettina and Donald Bryant Karyn and Stephen Khoury Jill and Sanford Sirulnick Ray and Dagmar Dolby $50,000–$99,999 Beacon Trust Pfizer Inc. CBS Corporation William P. Lauder Klara and Larry Silverstein Lynda and F. Davis Camalier Deborah and Peter Krulewitch Jean Kennedy Smith Family Fund Helen and Robert Appel Bloomberg L.P. Michael and Catherine Podell Linda and Arthur Carter The Alice Lawrence Mia and Sheldon Solow Caplan Family Dana and Michael Landow Debbie and Craig Stapleton Nancy and Melvin R. Goodes Renée and Robert Belfer Carol Seabrook Boulanger Ingeborg and Ira Rennert Michael T. Cohen Foundation, Inc. Mary R. Taylor Foundation Trust Estée Lauder Cosmetics Jeanette Sarkisian Wagner Carolyn and Malcolm Wiener Blavatnik Family Foundation Rose Marie Bravo and Margaret Rice Katherine and Michael Colby Linda and Steven Levy The Margaret and Daniel Allison Cooper Limited, UK Sara and John Walsh The Chisholm Foundation William Jackey Lois Robbins and Andrew Zaro Colliers International Serena and John Liew Loeb–Third Point Foundation Nancy Corzine Carole Cooper and Barbara Washkowitz $100,000–$249,999 Joyce Cowin Melanie and Louis Caceres Edmond Safra John D. Demsey Carlyn and John McCaffrey Alice and Thomas Tisch Bonnie M. Davis, MD and Richard Leibner Sue Ann Weinberg Caroline Fitzgibbons and Laurie Dowley and Caryn J. Clayman JP Morgan Chase Valerie and Charles Diker Lisa and Edward McLaughlin Barbara and Donald Tober Kenneth L. Davis, MD The Lerner Foundation Harriet and Ronald Weintraub Tad Smith Cynthia Breen Annette and Mitchell Eichen Janet Prindle Seidler Elizabeth & Richard Julie Medler Lorraine Wallace Jennie and Richard DeScherer Michelle MacDonald Wheels, Inc. Roslyn Goldstein Marlene Hess and James Zirin Ernst & Young LLP Foundation Dubin Foundation Merck Research Laboratories Jane Lauder and Kevin Warsh Douglas DiPasquale Holly and John Madigan Frances and Nathan Kirsh A.P. Kirby, Jr. Foundation, Inc. Marilyn and Sam Fox Susan and Peter Solomon Anne and Joel Ehrenkranz Dolby Family Ventures JoAnn and John Mason

*multi-year pledge

20 21 IN-KIND GIFTS Glorious Food Teuscher Chocolates of IN HONOR Noreen Miovski IN MEMORY Matthew Bucksbaum George Dietzen Robin Gerson Carolyn Jones A Mano, Inc. WDC GODIVA Chocolatier Switzerland In 2016, many generous gifts Laurie Monahan We remember advocates, Arthur Burdette Butts Lauretta Dowley Leon Gilbert Gerald Kaufman Abrielle Fine Linens and Tim Gunn The Estée Lauder were made to the ADDF in Sidney and Linda Moskowitz caregivers, and patients we William E. Burley Bernice Dressen Josephine Giordano Marion Kaufman Lingerie, Inc. Hamilton Farm Golf Club Companies Inc. honor of friends and loved ones. Lynn Mullen have lost by continuing to fight Mary Calandra Sheila and Arte Dribin James M. Goodman Marvin Kay Aimee Kestenberg Handbags Brett Heyman The Spa at the Peninsula Donald Newhouse for a cure. Blanche Charlotte Caplan Les Dunn Marica Goodwin Robert T. Kiernan & Accessories Oscar Heyman Brothers New York Philip Abraham Margaret “Maggie” O’Donoghue Richard “Dick” Capobianco Ruth Edrich Anne Gottlieb Dorothy Nell Kilgore Gatch Amangani KARMA by Erwin Gomez The Phillips Collection Shelley Banks Eileen Palevsky James Ackley Donna Carello Russell Eugene Edwards James Grant Anne Kincaid Amaryllis, Inc. Kendra Scott Sirio Ristorante Lillian Benson Rose Pastorino Lany Alexander Elaine Casey Barry Burt Efrus Monica Green Sally Korobkim Ann Hand LLC Deborah M. Krulewitch The Ritz-Carlton, Jeannine Bouillier-Siegmond Ginger Pickle Nimet Alisbach Catherine Caveny William Eisner Lefkowitz Sylvia Greenbaum Dorothy Koven AVENUE Magazine La Piquette Washington, DC Carol Seabrook Boulanger Pablo Reyes Elizabeth Alster Michael Cavuoti Bernice Elian Franco Grieco Evan Kramer Balance, Your Pilates, Yoga Bonnie E. Lautenberg St. Regis New York Chuck and Nancy Clarvit Phoebe Rice Sharon Anderson Alice Chambers Stone Jerry Engel Richard A. Guenther Rosa Kriger & Gyrotonic Studio Elise Lefkowitz Lorraine Wallace Jerome Cohen Sharon Rosenzweig-Lipson Barbara Anderson Moody Violette Chavanne Charles Evans Suzy Harper Overstreet Franklin W. Krum Barbara’s Flowers Philip H. Lovett Tina B. West Elaine Cole Selma Rowe Marilyn Aneser Melvin R. Clayman Edwin R. Everitt Irwin M. Hecht Joanne Ladd Faith Bobrow Mary’s Fish Camp Wolfgang’s Steakhouse Christy Davis & Paul Shatz Randal Sandler and Liz Furman Margaret Ashburner Ben Cohen Dr. Harold Feder Martin Heller Yvette Lafleur Bobbi Brown Monumental Sports Yuki Pearls Kevin Dieterich Anne Schmidt Ruth Bachrach Jerome M. Cohen Sanford Felberbaum Grace Helman Estée Lauder BrainHQ Entertainment Ruth Edrich John J. Shields, Sr. Pauline T. Baker Sara Cole Beatrice Fey Betty Herald Evelyn Lauder Buck’s Fishing & Camping Nancy Corzine Ralph Engel Alice Shure Naomi Banks Peggy Connelly Carol Fine Gloria Hirtz Lorine Lemons Bumble and bumble. Neiman Marcus Howard Fillit, MD Jean Steinberg Matilda Bartels Phil Connelly Lucille and Susan Fischer Sally Hokanson Ninfa Leo Café Milano Mazza Gallerie Michael Folio Elizabeth P. Stieg Rosemarie Bello Captain Paul Connolly Jonathan E. Franzblau Michael Hollander Lucille Leventhal Popik Chocolate Moose New York Nets, LLC Rose Furman Allen B. Swerdlick Agusta Bennett Bush Jerome Connolly Hennie Fredkin Carol C. Holmes Dora Levin City Winery Oscar de la Renta Roz Goldstein Donna Switzer Dave Berlin Paul Connolly Margaret Friedman Vincent Howlett Anne Lewaudoski Lynch Nancy Corzine Rasika West End Mel and Nancy Goodes Mary Rose Taylor Sophie Berlin Edna Constantine Sylvia Friedman John Hubbard Sturgis Eaton Frances Lewis Dalton Brody Rossano Ferretti Hairspa Robert Gruber The Lauder Family Lenore Black Agnes Cooney Farrell James W. Fry Christopher David Illick Shirley Lichaw Darphin RW Restaurant Group Madelyn B. Hannaway The Segal Family Bernard Bloom Antonio Coppola Jeanette Fuenning Kit Illick Virginia Loeb Weil Lab Series Sharon T. Sager Michael Juras Trish and George Vradenburg Jean Boilard Lois Courtney Rose Furman Mary S. Jackey Alfred “Al” Loecher dell’anima Hadley and John H. Scully Rita J. Kaplan Lorraine Wallace Ruth Boorstein Mary Louise Deal Rosemary Furman Naomi Jacobson Banks Jarman Lowder Design Cuisine Sherber+Rad Deborah Krulewitch Monty Waterbury Jacques Boulanger Julio DeLeon John Gaeitone John Jangl, Sr. Lucille Lowenthal Popik Feld Entertainment Signature Theatre – Leonard A. and Judy Lauder D. Martin Watterson Albino Braiuca Bessie Demestihas Sally Gale James F. Jerome Marcia Lubetz Goodwin Fiola Mare da Fabio Trabocchi Arlington, VA Ronald S. and Jo Carol Lauder Joan Wendt Ileana Bravo Audrey Dempsey Sylvia Gandelman David Johnson Chauncey F. Lufkin, Jr. Gillies Coffee Company, Sotheby’s Bonnie Englebart Lautenberg Jan Willinger Jean Brigati Nancy Denekas Estelle Gelman Diane M. Johnson Margaret Malone Brooklyn, NY Southwest Elise and Marc Lefkowitz Wendy Wilshin Barbara Brumley Willis Denekas Marilyn Gerber William Lee Johnson Gladys “Nanna” Manaster

22 23 Joan Mangam Wegner John R. O’Melia Manfred Schoen James Vince June and Charles Manheim Raymond James O’Melia Rudolph Scholbohm Eleanor Wall OUR STAFF Barbara Mann Reinfeld Joseph Owens Donald Schulman Francis E. Wall Yvonne Marandino Mary Patton Elaine and Gerald Schwartz Francis Webb Susan Marley Newhouse Richard Pearman Roz Schwartz Irving Weinberg Lois Marr Matthews Muriel Percy Lorrain Sciora Walter H. Weiner Diana Matt Arthur Pincus Anne Seabrook Peggie Sue Weir Mary Maughan Patton Lenore Pletcher Joseph J. Shepherd VII Janet Werkmeister EXECUTIVE DEVELOPMENT FINANCE & ADMINISTRATION Andrew Koemeter-Cox, PhD Dr. Jack Mausner Walter Poschmann Frances Sherwood Toby Wexler Howard Fillit, MD Melanie Beczak Diane Bartiromo Scientific Program Officer Jean Mazzei Jean Prentice Smith Ford John J. Shields, Sr. Louise Worley Founding Executive Director and Database Manager Associate Director, Finance and Janet J. McCall Josephine Quinn Catherine Shook Smithwick Henry Yates Chief Science Officer Administration Nick McKeehan Rodney McCann Robert Rapaport Robert Shulman Bertram Zeitel Rochelle Bloom Senior Program Manager, Aging and Marion McCormack Ronald Reagan Warren E. Siegmond Martin Zelman Mark Roithmayr Consultant Ethan Hutchinson Alzheimer’s Prevention Director, Finance and Administration Elliot McGrath Ethel Reardon Charlotte Simensky Chief Executive Officer Jessica Cavanaugh Heather Moore, JD Maureen McNalley Giroux Dorothy W. Reed Evelyn Singer Special Events Manager Katie Mischik Grants & Contracts Manager Daniel Melnick Sally and Rodney Rhoads Joyce Smith COMMUNICATIONS Executive Assistant to CEO Fred Meyer Connie Rice Gertrude Sokol Sumy Cho Steven Huang Diana Shineman, PhD Virginia D. Meyer Susan Rogers Battie Nicolas Spagna Digital Media Manager Development Associate Aspasia Moundros Senior Director, Scientific Affairs Betty Miller Jaime Roitman Sonny Spears Senior Executive Assistant to Anne Milstein Robert V. Roosa Leland Stanley Stires Krishna Knabe, MSc Jennifer Iselin Executive Director Dan Teng Gerald Moch Phyllis Rosenthal Anne Stoakes Director, Communications Director, Special Events Grants Associate Eloise Mondau Mary Lou Rossomando Oscar S. Straus II SCIENTIFIC AFFAIRS Linda Moore Joan Rotondi Yutaka Suzuki Jessica Levine Laura Morrison Sara Classen Stella Moses Vivian Salibello Wilma Jeanne Swartz Zulaut Graphic Design Manager Prospect Researcher and Assistant Director, Scientific Events Ellen Doris Nash Louis Santoro Irena Szancer Development Manager Ron and Virginia Nelson Dora Schapiro Alice Tabler Lauren Friedman, PhD Giorgio Zeolla Associate Director, Scientific Affairs Jose A. Nessim Sandra Schenkein Sylvia Tabor Shealy Director, Major Gifts Genevieve Norton Barbara Schild John Tazewell Yuko Hara, PhD Rosalind Obel Nadine Schiller Thomas L. Tiffany Assistant Director, Aging and Rosalie Offenhauser Anne Schmidt Rose Torres Alzheimer’s Prevention Jack O’Melia Naoma M. Schmidt Ernestine H. Turkus

24 25 OUR LEADERSHIP: OUR LEADERSHIP: The ADDF is led by two capable Boards who provide strategic vision, expert guidance, and a strong commitment to finding a BOARD OF GOVERNORS cure for Alzheimer’s and related dementias. BOARD OF OVERSEERS

HONORARY CHAIR Robert J. Appel Melvin R. Goodes* Steven Marc Paul, MD CHAIR Carol Seabrook Boulanger Philip Lovett Stephen Toma Justice Sandra Day O’Connor Chairman, Appel Associates Former Chairman and CEO, President and CEO, Voyager Sharon T. Sager Partner, Pillsbury, Winthrop, Shaw, Founding Partner, Managing Director, VJMS, LLC (Retired) Associate Justice, US Warner-Lambert Therapeutics, Inc. CIMA, Chair, Managing Director and and Pittman, LLP Millennium Partners Supreme Court Robert A. Belfer Private Wealth Advisor, UBS Private Wendy L. Wilshin Chairman, Belfer Management Nancy Goodes Lady Lynn Forester de Rothschild Wealth Management Charles Cangro Emilio Matt Founder and Principal, CO-CHAIRMEN Chief Executive, E.L. Rothschild LLC Principal, Personal Financial Services, Business Development Director, WLW Designs Leonard A. Lauder Roberta Diaz Brinton, PhD Gary Lauder Ernst & Young Microsoft Corporation Chairman Emeritus, The Estée Director, UA Center for Innovation Managing Director, Alice Shure Alison Zaino Lauder Companies Inc. in Brain Science at the University of Lauder Partners LLC Founder and Producer, AMICI Mitchell D. Eichen, JD, LL.M. Julie Medler Philanthropist Arizona Health Sciences Productions LLC; Co-Trustee, The Founder and CEO, Acertus Capital Managing Director, Ronald S. Lauder Laurence C. Leeds, Jr. Charles Evans Foundation Management, Founder and CEO, The Golden Seeds Linda S. Zambelli Chairman, Clinique Nancy Corzine Chairman, Buckingham MDE Group Managing Director, U.S. Trust, Bank of Laboratories, LLC President and CEO, Capital Management, Inc. Sally Susman* Pamela J. Newman, PhD America Private Wealth Management Nancy Corzine Inc. Executive Vice President, Policy, Allan M. Green, MD, PhD, JD President and CEO, The Newman VICE CHAIRMAN Bruce McEwen, PhD External Affairs and Communications, Allan M. Green Esq., LLC Team, Aon Corporation Randal Sandler Lanny Edelsohn, MD Alfred E. Mirsky Professor, Pfizer Inc. Director of Client Services Director, Christiana Care Health The Rockefeller University Christopher Johnson Phebe Farrow Port and Marketing, Bridgewater Systems, Inc. President and Managing Officer, SVP, Global Management Strategies; Associates Thomas F. McWilliams Paula Zahn Rackson Corporation Chief of Staff, Executive Management Bonnie Pfeifer Evans Managing Partner, Host and Executive Producer, Initiatives, The Estée Lauder EX OFFICIO Senior Sales Associate, Corcoran Group Court Square Capital Partners Discovery ID’s “On the Case with Bonnie Englebardt Lautenberg Companies Inc. Howard Fillit, MD Real Estate; Co-Trustee, The Charles Paula Zahn,” and WNET’s “NYC Arts” Photographer, Writer Founding Executive Director and Evans Foundation Richard Mohs, PhD John H. Scully, CIMA Chief Science Officer Retired VP for Neuroscience Early Elise Gelman Lefkowitz SVP, Global Private Client Group, Clinical Development and Distinguished Philanthropist Nuveen Investments Research Fellow, Eli Lilly & Company

26 27 STATEMENT OF ACTIVITIES 2016 FINANCIAL CHANGE IN NET ASSETS 2016 2015 Support and Revenues % OUR GROWING OVERVIEW Support Contributions and grants $ 17,768,167 17,524,509 INVESTMENTS In-kind services and contributions 100 Contributions of services from the Thanks to the generosity of our supporters, the amount we’ve STATEMENT OF FINANCIAL POSITION Institute for the Study of Aging, Inc. 3,682,032 3,098,678 Of Your Donation been able to invest in promising Alzheimer’s research programs $ ASSETS 2016 2015 Contributions of advertising – 440,200 has risen each year, increasing the number and diversity of 18.4 Million Cash and cash equivalents 4,955,417 4,903,074 Contributions of professional services – 35,000 Funds Science programs to advance along the drug development pipeline. Investments, at fair value 23,862,266 20,649,664 Proceeds from special events, $ net of direct expenses 4,038,612 3,590,294 All fundraising and management expenses are 14.5 Contributions receivable 16,433,336 4,962,392 Million Revenues underwritten by our founders, so your entire Program related investments – 536,800 donation funds the most innovative drug Grant returns, net of payments 471,094 920,018 Due from Institute for the research around the world. $ Study of Aging 75,712 82,008 Conference registration fees and $ 10.9 other income 194,269 335,118 9.9 Million Other assets 52,697 25,366 Million Investment income 576,947 4,668 $ Total assets $ 45,379,428 31,159,304 $ 8 Foreign Currency Exchange (loss) – (23,025) 6.9 Million Total support and revenues 26,731,121 25,925,460 Million LIABILITIES AND NET ASSETS Expenses Liabilities Program services 18,352,961 14,460,393 Accounts payable and accrued liabilities 7,818 100,536 Fundraising 1,643,278 1,772,890 Grants payable 21,761,264 13,504,012 Management and general 694,962 469,614 We’re proud to hold GuideStar’s highest Deferred revenue 19,350 3,680 Total expenses 20,691,201 16,702,897 charity rating. Total liabilities 21,788,432 13,608,228 Change in net assets 6,039,920 9,222,563 2011 2012 2013 2014 2015 2016 Total net assets 23,590,996 17,551,076 Net assets, beginning of year 17,551,076 8,328,513 Total liabilities and net assets $ 45,379,428 31,159,304 Net assets, end of year $ 23,590,996 17,551,076

* Preliminary draft of audited financials. Full audited 2016 financials available by request. 28 29 Accelerating the Discovery of Drugs to Prevent, Treat, and Cure Alzheimer’s Disease AlzDiscovery.org

57 West 57th Street, Suite 904 | New York, NY 10019 | 212.901.8000 | [email protected]